RxDoctor Payments Data

Lynn Preudhomme

Family · Phoenix, AZNPI 1538597885

Payments from drug & device makers

$753in general payments, 2019–2025

Across 37 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$123
  • Regeneron Healthcare Solutions, Inc.$116
  • AbbVie$109
  • GSK$100
  • Chiesi USA, Inc.$98
  • Vertex$35
  • plus $174 from 7 others

What the payments were for

  • Food & beverage$74198%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi6$123
Regeneron Healthcare Solutions, Inc.1$116
AbbVie5$109
GSK6$100
Chiesi USA, Inc.7$98
Vertex2$35
Gilead2$32
Mylan Specialty L.p.2$29
Digestive Care, Inc.1$28
Advanced Respiratory, Inc2$26
Genentech USA, Inc.1$25
Amgen1$20
PARI Respiratory Equipment, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$753 in reported general payments places this provider in the 60th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$6,216
Medicare patients
19
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft145$3,963,541
KalydecoIvacaftor26$741,325
CreonLipase/Protease/Amylase50$359,054
ZenpepLipase/Protease/Amylase23$205,559
CaystonAztreonam Lysine17$203,764
XolairOmalizumab24$94,021
PulmozymeDornase Alfa18$67,196
Advair HfaFluticasone Propion/Salmeterol26$21,120
DuleraMometasone/Formoterol15$4,838
Albuterol Sulfate HfaAlbuterol Sulfate46$1,622
Omeprazole19$284
Fluticasone Propionate23$247
Azithromycin18$237
Montelukast Sodium31$181
Alendronate Sodium20$120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
VertexTrikafta, Kalydeco$35$4,704,865171 claims
AbbVieCreon$109$359,05450 claims
GileadCayston$32$203,76417 claims
Genentech USA, Inc.Pulmozyme$25$67,19618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →